Article
CYP2E1 and risk of chemically mediated cancers.
Department of Pharmacology, University of Athens Medical School, 75 Mikras Asias Street, Athens, Greece.
Expert Opinion on Drug Metabolism & Toxicology (impact factor:
3.12).
03/2010;
6(3):307-19.
DOI:10.1517/17425250903540238
pp.307-19
Source: PubMed
-
Citations (0)
-
Cited In (0)
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
certain chemically-mediated cancers
certain CYP2E1 alleles
chemically-induced cancers
CYP2E1 'carcinogenic' polymorphisms
CYP2E1 gene
CYP2E1 gene transcription
CYP2E1 genetic polymorphisms
CYP2E1 inducers
CYP2E1 induction
CYP2E1 phenotype determination
CYP2E1-induced carcinogenesis
CYP2E1-mediated cancers
effective CYP2E1 inhibitors
first step
genetic polymorphism or/and gene induction
low molecular mass procarcinogens
malignant tumours
polymorphisms
susceptible subjects
various human CYPs